证券代码：688687 证券简称：凯因科技 公告编号：2023-042 北京凯因科技股份有限公司 关于调整 2021 年限制性股票激励计划授予价格 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于2023年8月24日召开第 五届董事会第十八次会议及第五届监事会第十二次会议，审议通过了《关于调整 2021年限制性股票激励计划授予价格的议案》,董事会同意将2021年限制性股票 激励计划(以下简称"激励计划")授予价格(含预留部分授予)由13.61元/股调 整为13.41元/股。现将有关事项说明如下: 一、本次激励计划已履行的决策程序和信息披露情况 （一）2021年4月20日，公司召开第四届董事会第十八次会议，审议通过了 《关于公司<2021年限制性股票激励计划（草案）>及其摘要的议案》《关于公司 <2021年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授 权董事会办理2021年限制性股票激励计划相关事宜的议案》等议案。公司独立董 事就激励计划相关议案发表了 ...

重要内容提示： 证券代码：688687 证券简称：凯因科技 公告编号：2023-028 北京凯因科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、参加人员 董事长兼总经理：周德胜先生 北京凯因科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 15:00-16:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2022年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2023 年 05 月 10 日(星期三)下午 15:00-16:00。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 192,744,105.30, representing a year-on-year increase of 12.34%[3] - The net profit attributable to shareholders decreased by 15.10% to CNY 21,139,765.72[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 52.88% to CNY 21,172,408.04[3] - The basic earnings per share for the period was CNY 0.12, down 20.00% year-on-year[3] - Net profit for Q1 2023 was CNY 22,354,935.04, a decrease of 4.1% from CNY 23,305,114.70 in Q1 2022[19] - Total comprehensive income for Q1 2023 was CNY 22,357,905.32, slightly lower than CNY 23,295,809.15 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was negative at CNY -91,540,826.82, a decrease of 264.28% compared to the previous year[3] - Cash flow from operating activities showed a net outflow of CNY -91,540,826.82 in Q1 2023, compared to a net inflow of CNY 55,722,465.48 in Q1 2022[23] - The net cash flow from investment activities was $140,779,144.98, compared to a negative cash flow of $932,482.69 in the previous year[25] - Total cash and cash equivalents at the end of the period amounted to $768,801,017.14, up from $720,692,506.40 at the beginning of the period[25] - Cash flow from financing activities resulted in a net outflow of $643,848.08, with cash paid for dividends and interest totaling $95,000.00[25] - The cash flow from investment activities saw an inflow of $627,408,629.14, significantly higher than the previous year's inflow of $80,537,500.28[25] - The cash outflow from investment activities was $486,629,484.16, compared to $81,469,982.97 in the same period last year[25] - The total cash and cash equivalents increased by $48,108,510.74 during the quarter[25] - The cash balance at the end of the period reflects a strong liquidity position for the company[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,148,238,860.72, a decrease of 2.78% from the end of the previous year[4] - The company's total liabilities decreased to RMB 444,090,790.95 from RMB 527,934,808.32, representing a reduction of about 15.9%[17] - The company's accounts receivable decreased to RMB 311,048,969.52 from RMB 333,297,094.96, indicating a decline of about 6.7%[15] - Inventory increased to RMB 167,939,662.52 from RMB 148,810,966.21, reflecting a rise of approximately 12.8%[15] - The company's equity attributable to shareholders rose to RMB 1,696,699,484.68 from RMB 1,675,556,748.68, an increase of about 1.3%[17] - The company's non-current assets totaled RMB 466,083,277.18, up from RMB 414,849,777.25, indicating an increase of approximately 12.3%[16] - Short-term borrowings decreased to RMB 10,686,242.00 from RMB 13,993,588.00, a decline of about 23.3%[16] - The company's total current liabilities decreased to RMB 396,437,608.90 from RMB 479,150,431.66, representing a reduction of approximately 17.2%[16] - The company reported a net profit increase in retained earnings to RMB 277,415,440.78 from RMB 256,275,675.06, reflecting a growth of about 8.4%[17] Research and Development - Research and development expenses totaled CNY 28,649,289.27, down 11.48% year-on-year, accounting for 14.86% of operating revenue, a decrease of 4 percentage points[4] - Research and development expenses increased to CNY 23,075,845.01 in Q1 2023, compared to CNY 21,549,143.45 in Q1 2022, marking an increase of 7.1%[19] - The company anticipates continued focus on R&D and market expansion strategies in the upcoming quarters[19] Shareholder Information - The company reported a total of 7,080 common shareholders at the end of the reporting period[10] - The top shareholder, Beijing Song'an Investment Management Co., Ltd., holds 22.47% of the shares, totaling 38,400,000 shares[11]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth [19]. - The company's operating revenue for 2022 was CNY 1,159,973,577.75, representing a 1.36% increase compared to CNY 1,144,356,833.98 in 2021 [25]. - The net profit attributable to shareholders for 2022 was CNY 83,407,819.44, a decrease of 22.26% from CNY 107,289,593.92 in 2021 [25]. - The basic earnings per share for 2022 was CNY 0.49, down 25.76% from CNY 0.66 in 2021 [26]. - The company's total assets at the end of 2022 were CNY 2,209,724,972.77, an increase of 1.47% from CNY 2,177,739,352.76 at the end of 2021 [25]. - The net cash flow from operating activities for 2022 was CNY 134,048,463.67, a 13.66% increase from CNY 117,938,941.70 in 2021 [25]. - The company achieved a total revenue of ¥1,159,973,577.75 in 2022, representing a year-on-year growth of 1.36% [92]. - The net profit attributable to shareholders decreased by 22.26% to ¥83,407,819.44 in 2022 [92]. - The company's total assets increased by 1.47% to ¥2,209,724,972.77 by the end of 2022 [92]. - The net cash flow from operating activities rose by 13.66% to ¥134,048,463.67 [92]. Research and Development - Research and development expenses accounted for 13.23% of operating revenue in 2022, an increase of 5.94 percentage points from 7.29% in 2021 [27]. - The company's R&D investment significantly increased to CNY 153.47 million, up 83.88% from the previous year, accounting for 13.23% of total revenue, an increase of 5.94 percentage points [34]. - The company has developed a multi-target, multi-mechanism R&D pipeline for the treatment of viral hepatitis B, including projects KW-001, KW-027, and KW-040 [55]. - The company’s R&D investment accounted for 13.23% of its operating revenue, which is higher than the industry average of 10.56% [135]. - The company has established a strong biopharmaceutical technology platform, participating in 7 national major science and technology projects [73]. - The company is focusing on innovative drug development for hepatitis B functional cure and immune disease treatment [128]. - The company has received multiple clinical trial approval notices for its products, including the interferon α2b spray for treating viral infections in children [131]. - The company has established partnerships with two leading research institutions to accelerate innovation in drug development [174]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years [19]. - The company plans to expand its mature product sales and enhance brand influence through targeted marketing strategies in hospitals and cancer screening initiatives [154]. - Market expansion plans include entering three new international markets by the end of 2023 [170]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 300 million RMB allocated for potential deals [174]. - The company’s sales strategy includes collaboration with qualified pharmaceutical distributors and contract sales organizations (CSOs) to enhance academic promotion and clinical application of new products [44]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2 CNY per 10 shares, totaling approximately 33.57 million CNY, which represents 40.25% of the net profit attributable to shareholders [6]. - The total share capital as of December 31, 2022, is 170,908,422 shares, with 167,872,598 shares being the basis for the dividend distribution after accounting for repurchased shares [6]. - The company has established a cash dividend policy, proposing to distribute at least 30% of the average distributable profit over any three consecutive years [199]. - The company’s cash dividend distribution is contingent upon having positive net profits and meeting operational funding needs [198]. Corporate Governance - The company has established a comprehensive governance structure, including a board of directors with four specialized committees to enhance decision-making efficiency [158]. - The company has maintained compliance with relevant laws and regulations regarding corporate governance, ensuring a robust operational framework [158]. - The company’s governance practices align with the requirements set forth by the China Securities Regulatory Commission, demonstrating adherence to regulatory standards [158]. - The company has not faced any major conflicts of interest or competitive issues with its controlling shareholders, maintaining a clear operational focus [159]. - All proposals at the shareholder meetings held in 2022 were approved without any dissenting resolutions, indicating strong shareholder support [161]. Product Development and Innovation - New product launches included two innovative drugs, expected to contribute approximately 200 million RMB in revenue in the next year [19]. - The company is focusing on the development of innovative drugs for functional cure of hepatitis B, with ongoing clinical trials for multiple projects [39]. - The company has developed a range of antiviral and immune-modulating products, including proprietary drugs like Paiyisheng® and Kainyisheng®, which are included in national essential drug lists and insurance directories [41]. - The company has successfully developed a pan-genotype oral drug series for hepatitis C, breaking the monopoly of foreign pharmaceutical companies in this area [152]. Financial Risks and Challenges - The company faces risks related to new drug development, including potential clinical trial failures and regulatory changes [75]. - The company is exposed to risks from fluctuations in the supply and prices of key raw materials necessary for production [83]. - The impact of national healthcare policy changes and centralized procurement on the company's pricing and sales strategies remains a concern [88]. - The company faces risks related to the potential replacement of short-acting interferon products by long-acting interferon products in the chronic hepatitis B market [80]. Employee and Management Information - Total compensation for all directors, supervisors, and senior management at the end of the reporting period amounted to 1,621.79 million [179]. - The company has increased its R&D personnel from 89 to 128, representing 18.80% of the total workforce, up from 13.76% [71]. - The company appointed a new deputy general manager, Du Zhenqiang, during the reporting period [180]. - The company has implemented a restrictive stock incentive plan, with various executives receiving shares as part of their compensation, indicating a focus on aligning management interests with shareholder value [163].

2022 年第三季度报告 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 343,845,209.70 | 35.70 | 836,731,606.49 | 18.43 | | ...

2022 年半年度报告 公司代码：688687 公司简称：凯因科技 北京凯因科技股份有限公司 2022 年半年度报告 1 / 179 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中详细阐述相关风险，敬请查阅本报告第三节"管理层讨论与分析"之"五、 风险因素"。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人周德胜、主管会计工作负责人郭伟及会计机构负责人（会计主管人员）刘洪娟声 明：保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、是否存在被控股股东及其关联方非经营性占用资金情况 否 十、是否存在违反规定决策程序对外提供担保的情况 ...

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第一季度报告 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 (一)主要会计数据和财务指标 | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年 | | | | | 同期增减变动幅 | | | | | 度(%) | | | 营业收入 | 171,572,290.44 | | -0.02 | | 归属于上市公司股东的净利润 | 24,898,632.42 | | 18.77 | | 归属于上市公司股东的 ...

2021 年年度报告 公司代码：688687 公司简称：凯因科技 北京凯因科技股份有限公司 2021 年年度报告 1 / 243 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 公司已在本报告中详细阐述相关风险，敬请查阅本报告第三节"管理层讨论与分析"之 "四、风险因素"。 四、 公司全体董事出席董事会会议。 五、 中汇会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人周德胜、主管会计工作负责人郭伟及会计机构负责人（会计主管人员）刘洪娟声 明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配方 案如下： 公司拟向全体股东每10股派发现金红利2.50元（含税）。截至2021年12月31日，公司总股本 169,828,422 ...

2021 年第三季度报告 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 253,383,909.53 | 14.34 | 706,514,61 ...

2021 年半年度报告 公司代码：688687 公司简称：凯因科技 北京凯因科技股份有限公司 2021 年半年度报告 1 / 189 2021 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中详细阐述相关风险，敬请查阅本报告第三节"管理层讨论与分析"之 "五、风险因素"。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人周德胜、主管会计工作负责人郭伟及会计机构负责人（会计主管人员）刘洪娟声 明：保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、是否存在被控股股东及其关联方非经营性占用资金情况 否 十、是否存在违反规定决策程序对外提供担保的情况？ 否 ...